Literature DB >> 19694765

Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.

S-J Liaw1, H-C Wu, P-R Hsueh.   

Abstract

This study investigated the microbiological characteristics of 100 clinical isolates of Cryptococcus neoformans species complex, including serotypes, mating types, molecular types, antifungal susceptibility and virulence. The isolates were collected at National Taiwan University Hospital from 1999 to 2004. Eight isolates of C. neoformans from pigeon droppings were also evaluated. Among these isolates, 99 were C. neoformans var. grubii serotype A and one was C. neoformans var. gattii serotype B. All of these isolates were alpha mating types. PCR fingerprinting, generated by primers M13 and (GACA)(4), and URA5 gene restriction fragment length polymorphism analysis revealed that C. neoformans var. grubii isolates belonged to the VNI (98 isolates) and the VNII (one isolate) types, and the single C. neoformans var. gattii was VGI type. The similar profiles of clinical and environmental isolates suggest that patients might acquire these yeasts from the environment. The MIC(90) for fluconazole, itraconazole, 5-flucytosine, voriconazole and amphotericin B against all C. neoformans isolates were 8, 0.5, 4, 0.125 and 0.5 mg/L, respectively. All clinical isolates produced urease, phospholipase, capsule and melanin, but these activities varied with individual isolates. Analysis of six clinical and two environmental isolates with various levels of phospholipase activity indicated a correlation between phospholipase activity and the ability to adhere to the lung epithelial cell line, A549. The extent of cell damage, as indicated by lactate dehydrogenase release, also paralleled the phospholipase activity of these isolates. In addition, production of melanin contributed significant protection against amphotericin B killing of the isolates tested.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19694765     DOI: 10.1111/j.1469-0691.2009.02930.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  19 in total

1.  Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population.

Authors:  Ferry Hagen; María-Teresa Illnait-Zaragozí; Jacques F Meis; William H M Chew; Ilse Curfs-Breuker; Johan W Mouton; Andy I M Hoepelman; Lodewijk Spanjaard; Paul E Verweij; Greetje A Kampinga; Ed J Kuijper; Teun Boekhout; Corné H W Klaassen
Journal:  J Clin Microbiol       Date:  2012-03-21       Impact factor: 5.948

2.  Refractory and/or Relapsing Cryptococcosis Associated with Acquired Immune Deficiency Syndrome: Clinical Features, Genotype, and Virulence Factors of Cryptococcus spp. Isolates.

Authors:  Erika Nascimento; Lucia H Vitali; Ludmilla Tonani; Marcia R Von Zeska Kress; Osvaldo M Takayanagui; Roberto Martinez
Journal:  Am J Trop Med Hyg       Date:  2016-02-29       Impact factor: 2.345

3.  Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea.

Authors:  Young Hwa Choi; Popchai Ngamskulrungroj; Ashok Varma; Edward Sionov; Soo Myung Hwang; Fabian Carriconde; Wieland Meyer; Anastasia P Litvintseva; Wee Gyo Lee; Jong Hee Shin; Eui-Chong Kim; Kyung Won Lee; Tae Yeal Choi; Yeong Seon Lee; Kyung J Kwon-Chung
Journal:  FEMS Yeast Res       Date:  2010-05-19       Impact factor: 2.796

4.  In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.

Authors:  Hin Siong Chong; Rebecca Dagg; Richard Malik; Sharon Chen; Dee Carter
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

Review 5.  Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility.

Authors:  Nina T Grossman; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

6.  Multilocus Sequence Typing of Clinical Isolates of Cryptococcus from India.

Authors:  Immaculata Xess; Mragnayani Pandey; Yubhisha Dabas; Reshu Agarwal; Shukla Das; Padma M V Srivastava; Rajeev Thakur; Shyama Sharma; Prashant Mani; Ashutosh Biswas; Dipankar Bhowmik; Bimal K Das; Rakesh Singh; Preetilata Panda; Gagandeep Singh; A C Phukan; Margaret Yhome; Chithra Valsan; Anupma Jyoti Kindo
Journal:  Mycopathologia       Date:  2021-01-20       Impact factor: 2.574

7.  ANTIFUNGAL SUSCEPTIBILITY TESTING AND GENOTYPING CHARACTERIZATION OF Cryptococcus neoformans AND gattii ISOLATES FROM HIV-INFECTED PATIENTS OF RIBEIRÃO PRETO, SÃO PAULO, BRAZIL.

Authors:  Thais Pandini Figueiredo; Rosymar Coutinho de Lucas; Rodrigo Anselmo Cazzaniga; Carolina Nunes França; Fernando Segato; Rafael Taglialegna; Claudia Maria Leite Maffei
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2016-09-22       Impact factor: 1.846

8.  Population genetic analyses reveal the African origin and strain variation of Cryptococcus neoformans var. grubii.

Authors:  Anastasia P Litvintseva; Thomas G Mitchell
Journal:  PLoS Pathog       Date:  2012-02-23       Impact factor: 6.823

9.  Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010.

Authors:  Hsiang-Kuang Tseng; Chang-Pan Liu; Mao-Wang Ho; Po-Liang Lu; Hsiu-Jung Lo; Yu-Hui Lin; Wen-Long Cho; Yee-Chun Chen
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Geographically structured populations of Cryptococcus neoformans Variety grubii in Asia correlate with HIV status and show a clonal population structure.

Authors:  Kantarawee Khayhan; Ferry Hagen; Weihua Pan; Sitali Simwami; Matthew C Fisher; Retno Wahyuningsih; Arunaloke Chakrabarti; Anuradha Chowdhary; Reiko Ikeda; Saad J Taj-Aldeen; Ziauddin Khan; Margaret Ip; Darma Imran; Ridhawati Sjam; Pojana Sriburee; Wanqing Liao; Kunyaluk Chaicumpar; Varaporn Vuddhakul; Wieland Meyer; Luciana Trilles; Leo J J van Iersel; Jacques F Meis; Corné H W Klaassen; Teun Boekhout
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.